686 / 1173
1/03/2016
25
Combretastatin-A4-phosphate + RT
•
Phase Ib trial in pts with NSCLC, PCa and HNSCC
•
Materials & Methods
•
Radiotherapy
•
CA4P:
•
dose-escalation from 50mg/m² to 63mg/m²
•
CA4P exposure increased from one to three to six doses
•
Patients with HNSCC received cetuximab in addition
•
Results: RT with CA4P appears well tolerated in most patients.
The combination of CA4P, cetuximab and RT needs further study
before it can be recommended for clinical studies.
NSCLC
PCa
HNSCC
RT
27Gy in 6fx, twice
daily over 3 weeks
55Gy in 20fx over 4
weeks
66Gy in 33fx over 6
weeks
Ng Ann Oncol 2012
Ribas, NEJM 2015